BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 23408967)

  • 1. Aberrant glycogen synthase kinase 3β is involved in pancreatic cancer cell invasion and resistance to therapy.
    Kitano A; Shimasaki T; Chikano Y; Nakada M; Hirose M; Higashi T; Ishigaki Y; Endo Y; Takino T; Sato H; Sai Y; Miyamoto K; Motoo Y; Kawakami K; Minamoto T
    PLoS One; 2013; 8(2):e55289. PubMed ID: 23408967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine.
    Shimasaki T; Ishigaki Y; Nakamura Y; Takata T; Nakaya N; Nakajima H; Sato I; Zhao X; Kitano A; Kawakami K; Tanaka T; Takegami T; Tomosugi N; Minamoto T; Motoo Y
    J Gastroenterol; 2012 Mar; 47(3):321-33. PubMed ID: 22041920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycogen synthase kinase-3β participates in acquired resistance to gemcitabine in pancreatic cancer.
    Uehara M; Domoto T; Takenaka S; Bolidong D; Takeuchi O; Miyashita T; Minamoto T
    Cancer Sci; 2020 Dec; 111(12):4405-4416. PubMed ID: 32986894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycogen synthase kinase 3β sustains invasion of glioblastoma via the focal adhesion kinase, Rac1, and c-Jun N-terminal kinase-mediated pathway.
    Chikano Y; Domoto T; Furuta T; Sabit H; Kitano-Tamura A; Pyko IV; Takino T; Sai Y; Hayashi Y; Sato H; Miyamoto K; Nakada M; Minamoto T
    Mol Cancer Ther; 2015 Feb; 14(2):564-74. PubMed ID: 25504636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycogen synthase kinase 3β promotes osteosarcoma invasion and migration via regulating PTEN and phosphorylation of focal adhesion kinase.
    Mai W; Kong L; Yu H; Bao J; Song C; Qu G
    Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 33969873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway.
    Namba T; Kodama R; Moritomo S; Hoshino T; Mizushima T
    Cell Death Dis; 2015 Jun; 6(6):e1795. PubMed ID: 26111057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy.
    Mamaghani S; Patel S; Hedley DW
    BMC Cancer; 2009 Apr; 9():132. PubMed ID: 19405981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GSK3beta and beta-catenin modulate radiation cytotoxicity in pancreatic cancer.
    Watson RL; Spalding AC; Zielske SP; Morgan M; Kim AC; Bommer GT; Eldar-Finkelman H; Giordano T; Fearon ER; Hammer GD; Lawrence TS; Ben-Josef E
    Neoplasia; 2010 May; 12(5):357-65. PubMed ID: 20454507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation.
    Ougolkov AV; Fernandez-Zapico ME; Bilim VN; Smyrk TC; Chari ST; Billadeau DD
    Clin Cancer Res; 2006 Sep; 12(17):5074-81. PubMed ID: 16951223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of protein kinase Cbeta by enzastaurin enhances radiation cytotoxicity in pancreatic cancer.
    Spalding AC; Watson R; Davis ME; Kim AC; Lawrence TS; Ben-Josef E
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6827-33. PubMed ID: 18006785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycogen synthase kinase 3β as a potential therapeutic target in synovial sarcoma and fibrosarcoma.
    Abe K; Yamamoto N; Domoto T; Bolidong D; Hayashi K; Takeuchi A; Miwa S; Igarashi K; Inatani H; Aoki Y; Higuchi T; Taniguchi Y; Yonezawa H; Araki Y; Aiba H; Minamoto T; Tsuchiya H
    Cancer Sci; 2020 Feb; 111(2):429-440. PubMed ID: 31808966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling.
    Xu BQ; Fu ZG; Meng Y; Wu XQ; Wu B; Xu L; Jiang JL; Li L; Chen ZN
    Oncotarget; 2016 Sep; 7(38):62177-62193. PubMed ID: 27556697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rab11a sustains GSK3β/Wnt/β-catenin signaling to enhance cancer progression in pancreatic cancer.
    Yu L; Li X; Li H; Chen H; Liu H
    Tumour Biol; 2016 Oct; 37(10):13821-13829. PubMed ID: 27481517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An emerging strategy for cancer treatment targeting aberrant glycogen synthase kinase 3 beta.
    Miyashita K; Nakada M; Shakoori A; Ishigaki Y; Shimasaki T; Motoo Y; Kawakami K; Minamoto T
    Anticancer Agents Med Chem; 2009 Dec; 9(10):1114-22. PubMed ID: 19925395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential therapeutic effect of glycogen synthase kinase 3beta inhibition against human glioblastoma.
    Miyashita K; Kawakami K; Nakada M; Mai W; Shakoori A; Fujisawa H; Hayashi Y; Hamada J; Minamoto T
    Clin Cancer Res; 2009 Feb; 15(3):887-97. PubMed ID: 19188159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
    Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
    Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines.
    Huanwen W; Zhiyong L; Xiaohua S; Xinyu R; Kai W; Tonghua L
    Mol Cancer; 2009 Dec; 8():125. PubMed ID: 20021699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts.
    Yau CY; Wheeler JJ; Sutton KL; Hedley DW
    Cancer Res; 2005 Feb; 65(4):1497-504. PubMed ID: 15735038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential therapeutic effect of targeting glycogen synthase kinase 3β in esophageal squamous cell carcinoma.
    Bolidong D; Domoto T; Uehara M; Sabit H; Okumura T; Endo Y; Nakada M; Ninomiya I; Miyashita T; Wong RW; Minamoto T
    Sci Rep; 2020 Jul; 10(1):11807. PubMed ID: 32678196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GSK3β inhibition blocks melanoma cell/host interactions by downregulating N-cadherin expression and decreasing FAK phosphorylation.
    John JK; Paraiso KH; Rebecca VW; Cantini LP; Abel EV; Pagano N; Meggers E; Mathew R; Krepler C; Izumi V; Fang B; Koomen JM; Messina JL; Herlyn M; Smalley KS
    J Invest Dermatol; 2012 Dec; 132(12):2818-27. PubMed ID: 22810307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.